Optimal INR level in Thai atrial fibrillation patients who were receiving warfarin for stroke prevention in Thailand.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet

• Publication date

  2014-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 25764634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of CYP2C9 and VKORC1 mutation in patients with valvular heart disease in northern Thailand.

  2009cited by this paper
• ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committe

  2006cited by this paper
• Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?

  2005influential reference
• The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.

  2005cited by this paper
• The Lowest Effective Intensity of Prophylactic Anticoagulation for Patients with Atrial Fibrillation

  2005influential reference
• Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

  2005cited by this paper
• American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

  2003cited by this paper
• Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

  2001cited by this paper
• Optimal Intensity of Warfarin Therapy for Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation

  2000influential reference
• Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

  2000cited by this paper
• Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  1999cited by this paper
• An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.

  1996cited by this paper
• Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.

  1995cited by this paper
• A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy

  1993influential reference

• 2025 Thai guideline for the diagnosis and management of atrial fibrillation

  2025influential citation
• The novel risk score model for predicting the poor anticoagulation control in patients with atrial fibrillation taking warfarin

  2025influential citation
• Efficacy and safety outcomes of patients with atrial fibrillation compared between warfarin and non-vitamin K antagonist oral anticoagulants based on SAMe-TT2R2 score

  2023cites this paper
• Net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation based on a CHA2DS2-VASc score

  2023cites this paper
• The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis

  2021cites this paper
• Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin

  2020cites this paper
• Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation.

  2020cites this paper
• Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand.

  2019cites this paper
• Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding

  2018influential citation